Login

Sildenafil Non-Responders: Haemodynamic and Morphometric Studies

Eric Wespes E, Rammal A, Garbar C; European Urology 2005 (48):136-139

KEY WORDS: Erectile dysfunction; PDE5 inhibitor; Sildenafil non-responder; Impotence

Erectile dysfunction (ED) is often associated with a cluster of risk factors for coronary artery disease and reduced endothelial function. Acute and chronic administration of oral sildenafil, a phosphodiesterase type 5 (PDE5) inhibitor, improves endothelial function in patients with ED. Tadalafil (TAD) is a new PDE5 inhibitor with a long half life that allows alternate day administration. Aim of the study was to evaluate whether chronic therapy (4 weeks) with TAD improves endothelial function in patients with increased cardiovascular risk and whether this effect is sustained after discontinuation of therapy.

See the abstract

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15967263&dopt=Citation